As anti-androgen therapy is a preferred clinical treatment option in AR-positive TNBC (7, 61–64), we compared the test compounds with clinically relevant anti-androgen, ENZ and chemotherapeutic, DTX, which inhibited tumor growth by 78.6% and 74.9%, respectively (Figures 8A–C). The gene discussed is AR; the disease is neoplasm.